摘要
目的评价和调查布地奈德/福莫特罗常规临床治疗哮喘的疗效和使用情况。方法开展多中心、开放的、非干预性调查研究,观察哮喘患者使用布地奈德/福莫特罗治疗12周后的哮喘控制情况,以哮喘控制调查问卷(ACQ)与改良的哮喘控制调查问卷(ACQ5)平均分值为主要疗效观察指标。结果共入选受试者360例,其中成人哮喘228例,儿童哮喘132例。经12周治疗后,所有患者ACQ平均分值由治疗前的2.03(成人2.20,儿童1.74)下降为0.60(成人0.78,儿童0.29),ACQ5平均分值由治疗前2.47(成人2.24,儿童1.76)下降为0.47(成人0.62,儿童0.20),差异均有统计学意义(P<0.0001)。结论布地奈德/福莫特罗在常规临床应用时可以有效地改善哮喘,并达到哮喘的良好临床控制。
Objective To evaluate the efficacy of Budesonide/formoterol to control asthma under real-life conditions. Methods A multi-center, open label, non-interventional study was conducted. Asthma control after 12 week therapy with Budesonide/formoterol was assessed by Asthma Control Questionnaire （ACQ） and modified Asthma Control Questionnaire （ACQS）. Results A total of 360 asthma patients were recruited,including 228 adult patients and 132 child patients. After 12 weeks＇ therapy, all the patients＇ medium value of ACQ was decreased significantly from 2. 03 （ adults 2. 20, children 1.74 ） at baseline to 0. 60 （ adults O. 78, children 0. 29 ） （ P 〈 0. 0001 ） , and the medium value of ACQ5 was also decreased significantly from 2. 4 （ adults 2. 24, children 1.76） at baseline to 0.47 （ adults 0. 62, children 0. 20 ） （ P 〈 0. 0001 ）. Conclusion Budesonide/formoterol is effective in asthma treatment, by which most asthma patients obtain and maintain clincal control.
出处
《中国呼吸与危重监护杂志》
CAS
2009年第4期341-344,共4页
Chinese Journal of Respiratory and Critical Care Medicine
